Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: A nested case-control study

BMJ Open

Volumn 3, Issue 2, 2013, Pages

  Erviti, Juan ^a   Alonso, Álvaro ^b,c   Gorricho, Javier ^a   López, Antonio ^a  

^a Navarre Regional Health Service   (Spain)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BIBLIOGRAPHIC DATABASE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INFORMATION; FEMALE; GENERAL PRACTICE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; RISK FACTOR; SPAIN; TREATMENT DURATION;

EID: 84875000966     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002084     Document Type: Article

References (22)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41. (Pubitemid 26411651)
2. Cummings SR, Black DM, Thompson D, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA 1998;280:2077-82. (Pubitemid 29014065)
3. Liberman UA, Weiss SR, Broll J, et al. Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
4. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997;82:265-74. (Pubitemid 27021310)
5. Reginster JY, Minne HW, Sorensen OH, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91. (Pubitemid 30099515)
6. Harris ST, Watts NB, Genent HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52. (Pubitemid 29483192)
7. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40. (Pubitemid 32107641)
8. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9. (Pubitemid 41094364)
9. Erviti J. Bisphosphonates: do they prevent or cause bone fractures? Drug Ther Bull 2009;17:65-75.
10. Therapeutics initiative. A systematic review of the efficacy of bisphosphonates. Ther Lett 2011;83:1-2.
11. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
12. Erviti J, Gorricho J. Use of alendronate after 5 years of treatment (letter). JAMA 2007;297:1979-81.
13. CHMP assessment report on bisphosphonates and osteonecrosis of the jaw. EMEA/CHMP/291125/2009. http://www.emea.europa.eu/ docs/en-GB/document-library/ Report/2010/01/WC500051428.pdf (accessed 2 Aug 2012).
14. FDA Drug Safety Communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ ucm229171.htm (accessed 2 Aug 2012).
15. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102.
16. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based National cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65.
17. Salvador JC, Moreno D, Sonego LA, et al. El Proyecto BIFAP: Base de datos para la Investigación. Aten Primaria 2002;30:655-61.
18. Agencia Española de Medicamentos y Productos Sanitarios. Proyecto BIFAP http://www.bifap.org/summary.php (accessed 22 Aug 2012).
19. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis. Where do we go from here? N Engl J Med 2012;366:2048-51.
20. Vlad SC, Zhu Y, Niu J, et al. Bisphosphonate use may be a risk factor for osteonecrosis at any site: a self-controlled case series analysis [abstract]. 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Chicago, 2011;[274].
21. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301. (Pubitemid 40463979)
22. Garjón Javier, J. Calcium supplements: are we doing it right? DTB Navarre 2012;20(3):1-12.